Author

S. Braga

Hospital Prof. Dr. Fernando Fonseca

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:differential expression· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Assay:bulk RNA-seq· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Jacinto· 3 shared M. G. Cabral· 3 shared D. P. Saraiva· 2 shared R. Salvador· 2 shared A. Antunes· 1 shared A. Jacinta-Fernandes· 1 shared A. T. Matias· 1 shared A.-T. Maia· 1 shared

Activity by Year

2020-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Jacinto

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Enhancing HLA-DR in Cytotoxic T Lymphocytes is crucial for the development of efficient adoptive T cell Therapies for Breast Cancer

Rute M. Salvador, Bruna Correia, D.S.C.P. Grosa, Telma Martins, Suelen Cristina Soares Baal, Diana P. Saraiva, Sofia Cristóvão‐Ferreira, I. L. Pereira, Cátia Rebelo de Almeida, Rita Fior, António Jacinto, Carolina Mathias, S. Braga, Maria Guadalupe Cabral

This study shows that enhancing HLA-DR expression in cytotoxic T lymphocytes improves their anti-tumor activity, suggesting strategies to optimize adoptive T cell therapies for breast cancer.

Frontiers in Immunology · Sep 19, 2025Peer-reviewedImmunology

Determination of HLA-DR level in cytotoxic T lymphocytes: a new validated tool to predict breast cancer response to treatment

D. P. Saraiva, S. Azeredo-Lopes, A. Antunes, R. Salvador, P. Borralho, B. Assis, I. Pereira, Z. Seabra, I. Negreiros, A. Jacinto, S. Braga, M. G. Cabral

This paper validates HLA-DR expression in cytotoxic T lymphocytes as a predictive biomarker for breast cancer response to neoadjuvant chemotherapy and shows its association with progression-free survival.

bioRxiv · Apr 29, 2021 · PreprintImmunology

Circulating Low Density Neutrophils of Breast Cancer Patients are Associated with their Worse Prognosis due to the Impairment of T cell Responses

D. P. Saraiva, B. F. Correia, R. Salvador, N. de Sousa, A. Jacinto, S. Braga, M. G. Cabral

This study shows that low density neutrophils (LDN) in breast cancer patients are linked to worse prognosis due to their immunosuppressive effects on T cell responses.

bioRxiv · Feb 19, 2021 · PreprintImmunology

Differential expression between African-ancestry and White patients diagnosed with Triple-Negative Breast Cancer: EGFR, Myc, Bcl2 and β-Catenin as ancestry-associated markers

A. T. Matias, A. Jacinta-Fernandes, A.-T. Maia, S. Braga, A. Jacinto, M. G. Cabral, P. H. Brito

This study identifies ancestry-associated gene and protein expression differences in Triple-Negative Breast Cancer between African-ancestry and White patients, highlighting EGFR, Myc, Bcl2, and β-Catenin as potential markers.

bioRxiv · Nov 13, 2020 · PreprintCancer Biology